The Ghoulish Gamechanger - Exposing Obesity Incorporated S1 E6

Get full show notes, links, and transcript at: https://www.ExposingObesityIncoporate... Ragen Chastain and Louise Adams examine whether GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are really the “game changers” they’re marketed to be. They trace how Novo Nordisk built a long-term strategy around weight loss, unpacking the gap between the hype, the trial data, and the real-world harms. They reveal how the drugs were positioned, how the definition of “clinically significant” weight loss was repeatedly lowered, and why the “lifelong chronic disease” framing is so profitable. The episode also covers marketing ethics, compounding battles, shortages, side effects, and the use of industry funded “education” to sell a message. Timestamps 00:00 - Welcome to the podcast and the “Ghoulish Game Changer” 01:21 - What Novo Nordisk has built over the last five episodes 03:06 - GLP-1s as diabetes drugs with a weight loss side effect 03:59 - The rat study that showed GLP-1s suppress eating 05:17 - Victoza, off-label weight loss, and the five-pound-a-year reality 06:37 - Saxenda and the move to a dedicated weight loss dose 07:37 - Semaglutide and the push for weekly injections 08:11 - Lars Jorgensen’s shareholder messaging and the 15% promise 09:45 - Regulatory pressure, insulin pricing, and legal trouble 11:10 - FDA priority vouchers and how Wegovy got accelerated 13:01 - The “blockbuster” rollout and the 15% weight loss headline 14:01 - How the bar for “clinically significant” weight loss kept shrinking 16:08 - Why weight loss alone does not equal health improvement 17:36 - Dr. Oz, Robert Kushner, and media amplification 20:37 - Insurance coverage lobbying and Medicare as the holy grail 22:57 - Novo’s PSA using TV doctors instead of doctors 26:10 - Co-opting anti-stigma work to sell weight loss drugs 27:10 - The “It’s Bigger Than Me” campaign 28:49 - Rethink Oplesity and marketing disguised as education 29:41 - Why these drugs are not a special kind of fat loss 31:34 - Mechanical effects, slowed digestion, and common GI side effects 32:52 - Crossing the blood-brain barrier and disrupting hunger signals 34:27 - Reward flattening, mood effects, and loss of pleasure 35:58 - What the trials actually show versus the marketing claims 36:52 - Weight regain after stopping and the lifelong disease narrative 40:45 - Side effects, severe risks, and the thyroid cancer warning 43:46 - Trial attrition and why four-year claims are misleading 46:08 - Novo’s secret parties and the money pouring in 48:07 - Manufacturing shortages and the collapse of supply 50:35 - Redirecting diabetes supply to the weight loss market 53:04 - The compounding loophole and 503B pharmacies 55:17 - Super Bowl ads, lawsuits, and the shortage fight 56:40 - Personalized dosing and the compounding workaround 57:09 - Novo’s failed partnership with Hims and Hers 57:54 - Stock drops, leadership fallout, and selective concern 60:13 - The episode’s bottom line: the game is rigged The views and opinions expressed here are our own. All claims are alleged unless otherwise specified. This podcast is for informational purposes only and does not constitute medical, legal, or financial advice. Please consult with a professional for specific advice tailored to your situation. Code: 0OKRSW6IKVNAXE25